Congress Programme

Friday, September 23

8.30–9.00 Coffee, posters
9.00–9.45 Plenary session
Biological and analytical variation of biomarkers
Glass Hall
Sverre Sandberg, Norway

9.50–11.30 | Morning sessions

Session 1 Hematology and coagulation
Moderators: Karel Tomberg, Estonia; Ludmila Volozonoka, Latvia; Valdas Banys, Lithuania
Glass Hall
9.50-10.10 Hemogram reference values ​​in Estonia Karel Tomberg, Estonia; Marika Pikta, Estonia
10.10-10.30 Comparison of automated red cell parameters with bone marrow iron staining Triin Paabo, Estonia
10.30-10.50 Multiple myeloma immunophenotype related to genetic aberrancies used in risk stratification Mantas Radzevičius, Lithuania
10.50-11.10 Clinical implications of genetic testing for thrombophilia Ludmila Volozonoka, Latvia
11.10-11.30 Added-value of viscoelastic assays in haemostasis evaluation in patients undergoing invasive procedures Daiva Urbonienė, Lithuania
Session 2 Clinical genetics and rare diseases
Moderators: Neeme Tõnisson, Estonia; Inga Nartisa, Latvia
Hall 2+3
9.50-10.10 Advances in rare disease diagnostics and research Sander Pajusalu, Estonia
10.10-10.30 Hyperphenylalaninemias and neurophysiological disorders Hardo Lilleväli, Estonia
10.30-10.50 Novel genetic methods for improved diagnostics of inborn errors of immunity Inga Nartisa, Latvia
10.50-11.10 Delineation of the genetic causes of rare diseases by the use of NGS and functional studies Gunda Petraitytė, Lithuania
11.10-11.30 nDNA and mtDNA analysis of patients with suspected mitochondrial disease:  a wide diagnostic spectrum Kristina Grigalionienė, Lithuania
11.30–12.00 Coffee break, posters
12.00–12.30 Roche Cardiovascular disease solutions: helping to solve challenges and unmet needs with high medical value tests – Aleksandra Lezaja, PhD, Associate Medical Affairs Manager Cardiovascular & Metabolism Disease Area. Clinical Development and Medical Affairs (Roche Diagnostics International) Glass Hall (Commercial presentation)
12.00–12.30 The Roche portfolio of digital solutions connects the healthcare community – Jaroslav Vohánka, Digital Business Manager Central & Eastern Europe (Roche Information Solutions) Hall 2+3 (Commercial presentation)
12.35–14.10 | Mid-day sessions
Session 3 Quality management
Moderators: Agnes Ivanov, Estonia; Dalius Vitkus, Lithuania
Glass Hall
12.35-13.05 The new IVD Regulation 2017/746: Where we are? Elisabeth M.C. Dequeker, Belgium
13.05-13.35 EQA of 2020’s: needs and trends Dalius Vitkus, Lithuania
13.35-13.50 Compliance of blood sampling practice in Lithuania with the EFLM-COLABIOCLI recommendations Ričardas Stonys, Lithuania
13.50-14.10 Quality of laboratory results. Definition and estimation Anders Kallner, Sweden
Session 4 Microbiology and infectious diseases. Zoonoses.
Moderators: Irja Lutsar, Estonia; Aleksandra Rudzāte, Latvia; Asta Dambrauskiene, Lithuania
Hall 2+3
12.35-13.05 Emerging and re-emerging infectious diseases in 2022 Irja Lutsar, Estonia
13.05-13.20 Tick-borne pathogens Julia Geller, Estonia
13.20-13.35 Zoophilic dermatophytes Piia Hurt, Estonia
13.35-13.50 HORIZON 2020 PERFORM and DIAMONDS projects: new genomic and proteomic approaches to provide rapid and accurate diagnosis of febrile illnesses – turning fiction into a reality Aleksandra Rudzāte, Latvia
13.50-14.05 Etiologic agents of community acquired and nosocomial bacteremias, differences in antimicrobial susceptibility Asta Dambrauskiene, Lithuania
14:15–15.15 Lunch, posters
15.15–15.45 Expediting the diagnosis of Myocardial Infarction: which role can hs-cTn at the Point-of-Care play? – Niels Kramer (Siemens Healthineers) Glass Hall (Commercial presentation)
15.15–15.45 mTBI – game changing assay – Markus Hoffmann (Abbott Germany) Hall 2+3 (Commercial presentation)
16.00–17.30 | Afternoon sessions
Session 5 New Biomarkers in Laboratory Medicine
Moderators: Kalle Kisand, Estonia; Baiba Šlisere, Latvia, Dovilė Karčiauskaitė, Lithuania
Glass Hall
16.00-16.30 Enhanced Liver Fibrosis (ELF) score in the general population Fredrik Åberg, Finland
16.30-16.50 Uncovering the impact of weight loss on biomarkers of obesity Baiba Šlisere, Latvia
16.50-17.10 Therapeutic Drug Monitoring in the Era of LC-MS/MS in the Laboratory Without LC-MS/MS Jānis Meisters, Latvia
17.10-17.30 CEACAM6 as a diagnostic and prognostic biomarker of pancreatic adenocarcinoma Benediktas Kurlinkus, Lithuania
Session 6 Cancer Screening today and tomorrow
Moderators: Katrin Reimand, Estonia; Neeme Tõnisson, Estonia
Hall 2+3
16.00-16.20 Colorectal cancer screening – Latvian experience Tatjana Zablocka, Latvia
16.20-16.40 Estonian experience in colorectal cancer screening Katrin Reimand, Estonia
16.40-17.00 Colorectal cancer screening in Lithuania Vytenis Petkevicius, Lithuania
17.00-17.20 Perspectives of personalized breast cancer screening Neeme Tõnisson, Estonia
19.30–23.00 Congress dinner Seaplane Harbour